Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dianthus Therapeutics, Inc. (DNTH)
USD98.88
+0.24 (+0.24%)
US NASDAQ Healthcare Biotechnology
Address
7 Times Square 10036
New York, NY, US
New York, NY, US
CEO
Marino Garcia
Website
dianthustx.com
IPO
2018-06-21
CIK 1690585 ISIN US2528281080
Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD98.88
+0.24 (+0.24%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
889.1K
Beta
0.07
Float Shares
29.16M
Free Float %
69.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.37% | +6.25% | +5.93% | +68.53% | +111.48% | +125.70% | +434.85% | +818.16% | -54.97% | -59.96% | -59.96% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
98.88
Low
55.00
-44.4%
Consensus
111.91
+13.2%
Median
120.00
+21.4%
High
145.00
+46.6%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 16 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
122.50
+23.9%
|
| Last Quarter | 10 |
117.60
+18.9%
|
| Last Year | 17 |
99.29
+0.4%
|
| All Time | 19 |
94.26
-4.7%
|
Quality scores
Altman Z-Score
47.76
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-67.4% Q1'26: -60.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-64.7% Q1'26: -3.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-7,917.8% Q1'26: -6,234.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-8,739.3% Q1'26: -10,050.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-196.6% Q1'26: -203.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+13.5% Q1'26: +34.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 9 EPS Ana. |
Dec 2027 9 Rev. Ana. 9 EPS Ana. |
Dec 2028 11 Rev. Ana. 11 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
2.83M
est: 3.22M (-12.3%)
|
6.24M
est: 5.54M (+12.5%)
|
2.04M
est: 2.20M (-7.3%)
|
1.18M
411.4K – 1.75M
-46.2% YoY
|
1.67M
781.1K – 2.53M
+41.3% YoY
|
15.74M
6.90M – 23.77M
+843.8% YoY
|
195.75M
85.80M – 295.66M
+1,143.7% YoY
|
618.26M
271.00M – 933.84M
+215.8% YoY
|
| EBITDA |
-47.82M
est: -3.22M (-1,383.2%)
|
-101.45M
est: -5.54M (-1,729.9%)
|
-177.93M
est: -2.20M (-8,004.0%)
|
-1.18M
-1.75M – -411.4K
+46.2% YoY
|
-1.67M
-2.53M – -781.1K
-41.3% YoY
|
-15.74M
-23.77M – -6.90M
-843.8% YoY
|
-195.75M
-295.66M – -85.80M
-1,143.7% YoY
|
-618.26M
-933.84M – -271.00M
-215.8% YoY
|
| EBIT |
-48.17M
est: -3.22M (-1,394.2%)
|
-101.86M
est: -5.54M (-1,737.3%)
|
-177.93M
est: -2.20M (-8,004.0%)
|
-1.18M
-1.75M – -411.4K
+46.2% YoY
|
-1.67M
-2.53M – -781.1K
-41.3% YoY
|
-15.74M
-23.77M – -6.90M
-843.8% YoY
|
-195.75M
-295.66M – -85.80M
-1,143.7% YoY
|
-618.26M
-933.84M – -271.00M
-215.8% YoY
|
| Net Income |
-43.56M
est: -50.21M (+13.3%)
|
-84.97M
est: -100.73M (+15.6%)
|
-162.34M
est: -173.66M (+6.5%)
|
-144.22M
-175.18M – -113.27M
+17.0% YoY
|
-162.07M
-199.19M – -124.95M
-12.4% YoY
|
-162.72M
-225.99M – -99.44M
-0.4% YoY
|
-118.36M
-196.90M – -31.94M
+27.3% YoY
|
87.72M
23.67M – 145.92M
+174.1% YoY
|
| SGA |
18.16M
est: 19.13M (-5.1%)
|
24.99M
est: 32.90M (-24.0%)
|
34.33M
est: 13.03M (+163.5%)
|
7.01M
2.44M – 10.40M
-46.2% YoY
|
9.90M
4.64M – 15.03M
+41.3% YoY
|
93.41M
40.94M – 141.09M
+843.8% YoY
|
1.16B
509.19M – 1.75B
+1,143.7% YoY
|
3.67B
1.61B – 5.54B
+215.8% YoY
|
| EPS |
-8.45
est: -4.42 (-91.0%)
|
-2.55
est: -2.56 (+0.4%)
|
-4.20
est: -3.68 (-14.2%)
|
-3.68
-4.64 – -3.00
-0.1% YoY
|
-4.45
-5.27 – -3.31
-20.8% YoY
|
-4.94
-5.98 – -2.63
-11.0% YoY
|
-3.13
-5.21 – -0.85
+36.5% YoY
|
2.32
0.63 – 3.86
+174.1% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | Wedbush | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-138.89M
OE per share TTM
-3.54
Owner's Yield
-3.11%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
162.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
250
Total invested
5.17B
Insider transactions (90d)
8
Beneficial owners (>5%)
8
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Octagon Capital Advisors LP | 1.75M | 6.00% | — | 1.75M | — | 1.75M | IA, PN | Delaware | 2024-10-11 | ↗ |
| 2 | Ting Jia | 1.75M | 6.00% | — | 1.75M | — | 1.75M | HC, IN | Delaware | 2024-10-11 | ↗ |
| 3 | (1) BlackRock, Inc. | 1.64M | 5.60% | 1.62M | — | — | 1.62M | HC | Delaware | 2024-11-08 | ↗ |
| 4 | Chen Yu | 1.50M | 5.10% | — | 1.50M | — | 1.50M | IN | Delaware | 2024-11-22 | ↗ |
| 5 | TCG Crossover Fund II, L.P. | 1.50M | 5.10% | — | 1.50M | — | 1.50M | PN | Delaware | 2024-11-22 | ↗ |
| 6 | TCG Crossover GP II, LLC | 1.50M | 5.10% | — | 1.50M | — | 1.50M | OO | Delaware | 2024-11-22 | ↗ |
| 7 | Octagon Investments Master Fund LP | 1.46M | 5.00% | — | 1.46M | — | 1.46M | PN, OO | Delaware | 2024-10-11 | ↗ |
| 8 | Octagon Private Opportunities Fund II LP | 291.7K | 1.00% | — | 291.7K | — | 291.7K | PN, OO | Delaware | 2024-10-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
250
+81 vs prev Q
New positions
97
Closed positions
21
Increased
179
Reduced
56
Put/Call ratio
1.10
Calls held
231.8K
Puts held
256.1K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 297.4K +297.4K (+100.0%) | 12.26B +12.3B (+100.0%) | 0.79% +0.787 pp | 4.05% +4.050 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 2 | FMR LLC | 6.43M +460.7K (+7.7%) | 265.04M +30.1M (+12.8%) | 17.02% +0.349 pp | 0.01% +0.001 pp | USD26.88 +53.3% | 10 qtrs — |
| 3 | WELLINGTON MANAGEMENT GROUP LLP | 2.50M -74.5K (-2.9%) | 103.16M +1.7M (+1.7%) | 6.62% -0.573 pp | 0.02% +0.000 pp | USD38.94 +5.8% | 6 qtrs — |
| 4 | OCTAGON CAPITAL ADVISORS LP | 2.42M +— (+0.0%) | 99.59M +4.5M (+4.7%) | 6.39% -0.352 pp | 12.09% -2.323 pp | USD23.81 +73.1% | 10 qtrs — |
| 5 | FAIRMOUNT FUNDS MANAGEMENT LLC | 2.14M -1.2M (-35.4%) | 88.07M -42.1M (-32.3%) | 5.65% -3.577 pp | 6.70% -5.005 pp | USD22.30 +84.8% | 10 qtrs — |
| 6 | AVIDITY PARTNERS MANAGEMENT LP | 2.10M -1.1M (-34.3%) | 86.71M -39.4M (-31.2%) | 5.57% -3.377 pp | 25.01% -3.684 pp | USD30.41 +35.5% | 10 qtrs — |
| 7 | VANGUARD GROUP INC | 2.05M +406.3K (+24.7%) | 84.42M +19.8M (+30.6%) | 5.42% +0.836 pp | 0.00% +0.000 pp | USD29.73 +38.6% | 10 qtrs — |
| 8 | BLACKROCK, INC. | 1.92M +575.1K (+42.9%) | 78.93M +26.2M (+49.7%) | 5.07% +1.327 pp | 0.00% +0.000 pp | USD31.52 +30.7% | 6 qtrs — |
| 9 | TCG CROSSOVER MANAGEMENT, LLC | 1.68M +— (+0.0%) | 69.09M +3.1M (+4.7%) | 4.44% -0.244 pp | 2.29% -0.959 pp | USD23.63 +74.4% | 5 qtrs — |
| 10 | RA CAPITAL MANAGEMENT, L.P. | 1.61M -1.3M (-43.8%) | 66.42M -46.4M (-41.1%) | 4.26% -3.738 pp | 0.68% -0.710 pp | USD25.68 +60.5% | 8 qtrs — |
| 11 | STATE STREET CORP | 1.51M +836.6K (+124.7%) | 62.13M +35.7M (+135.3%) | 3.99% +2.116 pp | 0.00% +0.001 pp | USD35.08 +17.5% | 8 qtrs — |
| 12 | BRAIDWELL LP | 1.27M +438.9K (+52.6%) | 52.50M +19.6M (+59.8%) | 3.37% +1.040 pp | 1.68% +0.704 pp | USD39.99 +3.1% | 7 qtrs — |
| 13 | POINT72 ASSET MANAGEMENT, L.P. | 1.17M -875.9K (-42.9%) | 48.05M -32.3M (-40.2%) | 3.09% -2.615 pp | 0.05% -0.081 pp | USD25.79 +59.8% | 8 qtrs — |
| 14 | CITADEL ADVISORS LLC | 1.07M +55.4K (+5.5%) | 44.05M +4.2M (+10.5%) | 2.83% -0.001 pp | 0.01% +0.001 pp | USD28.09 +46.7% | 10 qtrs — |
| 15 | MARSHALL WACE, LLP | 1.01M +435.6K (+76.0%) | 41.56M +19.0M (+84.3%) | 2.67% +1.069 pp | 0.04% +0.015 pp | USD40.15 +2.6% | 2 qtrs — |
| 16 | POLAR CAPITAL HOLDINGS PLC | 1.00M +256.7K (+34.3%) | 41.40M +12.0M (+40.7%) | 2.66% +0.570 pp | 0.16% +0.018 pp | USD39.83 +3.5% | 2 qtrs — |
| 17 | VR ADVISER, LLC | 1.00M +39.2K (+4.1%) | 41.21M +3.4M (+9.0%) | 2.65% -0.036 pp | 2.04% -0.092 pp | USD23.34 +76.6% | 10 qtrs — |
| 18 | ALLIANCEBERNSTEIN L.P. | 834.4K -18.0K (-2.1%) | 34.38M +843.6K (+2.5%) | 2.21% -0.172 pp | 0.01% +0.000 pp | USD25.72 +60.2% | 7 qtrs — |
| 19 | BAKER BROS. ADVISORS LP | 789.8K +— (+0.0%) | 32.55M +1.5M (+4.7%) | 2.09% -0.115 pp | 0.19% -0.034 pp | USD18.63 +121.2% | 3 qtrs — |
| 20 | SILVERARC CAPITAL MANAGEMENT, LLC | 750.1K +75.2K (+11.1%) | 30.91M +4.4M (+16.4%) | 1.98% +0.101 pp | 4.29% +0.712 pp | USD36.83 +11.9% | 4 qtrs — |
| 21 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 743.6K -572.3K (-43.5%) | 30.64M -21.1M (-40.8%) | 1.97% -1.706 pp | 2.35% -1.090 pp | USD29.71 +38.7% | 8 qtrs — |
| 22 | GEODE CAPITAL MANAGEMENT, LLC | 676.7K +140.2K (+26.1%) | 27.89M +6.8M (+32.1%) | 1.79% +0.293 pp | 0.00% +0.000 pp | USD30.78 +33.9% | 10 qtrs — |
| 23 | MILLENNIUM MANAGEMENT LLC | 667.2K +521.1K (+356.5%) | 27.50M +21.7M (+378.1%) | 1.77% +1.357 pp | 0.01% +0.009 pp | USD36.26 +13.7% | 9 qtrs — |
| 24 | CATALIO CAPITAL MANAGEMENT, LP | 653.6K -14.0K (-2.1%) | 26.93M +663.1K (+2.5%) | 1.73% -0.134 pp | 4.76% -0.096 pp | USD21.80 +89.0% | 5 qtrs — |
| 25 | TRI LOCUM PARTNERS LP | 622.4K +439.5K (+240.4%) | 25.65M +18.5M (+256.4%) | 1.65% +1.136 pp | 3.33% +1.677 pp | USD40.66 +1.4% | 2 qtrs — |
| 26 | PRICE T ROWE ASSOCIATES INC /MD/ | 616.0K +399.9K (+185.0%) | 25.39M +16.9M (+198.5%) | 1.63% +1.027 pp | 0.00% +0.002 pp | USD40.32 +2.2% | 6 qtrs — |
| 27 | UBS GROUP AG | 606.6K +469.5K (+342.6%) | 25.00M +19.6M (+363.5%) | 1.61% +1.222 pp | 0.00% +0.003 pp | USD36.80 +12.0% | 10 qtrs — |
| 28 | GOLDMAN SACHS GROUP INC | 577.0K +358.2K (+163.8%) | 23.78M +15.2M (+176.2%) | 1.53% +0.916 pp | 0.00% +0.002 pp | USD33.09 +24.5% | 8 qtrs — |
| 29 | BNP PARIBAS ARBITRAGE, SNC | 475.7K +441.2K (+1,275.3%) | 19.61M +18.2M (+1,340.3%) | 1.26% +1.162 pp | 0.01% +0.008 pp | USD39.57 +4.1% | 5 qtrs — |
| 30 | SIO CAPITAL MANAGEMENT, LLC | 474.5K -103.2K (-17.9%) | 19.55M -3.2M (-14.0%) | 1.26% -0.357 pp | 3.08% -2.678 pp | USD30.78 +33.9% | 4 qtrs — |
| 31 | BANK OF AMERICA CORP /DE/ | 465.5K +285.5K (+158.6%) | 19.18M +12.1M (+170.8%) | 1.23% +0.729 pp | 0.00% +0.001 pp | USD34.52 +19.4% | 10 qtrs — |
| 32 | FRANKLIN RESOURCES INC | 462.8K +12.5K (+2.8%) | 19.07M +1.4M (+7.6%) | 1.22% -0.033 pp | 0.00% +0.000 pp | USD39.40 +4.6% | 2 qtrs — |
| 33 | NANTAHALA CAPITAL MANAGEMENT, LLC | 375.0K +— (+0.0%) | 15.45M +697.5K (+4.7%) | 0.99% -0.055 pp | 0.51% -0.002 pp | USD39.35 +4.7% | 2 qtrs — |
| 34 | VIVO CAPITAL, LLC | 354.0K +— (+0.0%) | 14.59M +658.4K (+4.7%) | 0.94% -0.052 pp | 0.94% -0.178 pp | USD39.35 +4.7% | 2 qtrs — |
| 35 | GREAT POINT PARTNERS LLC | 350.0K +84.2K (+31.7%) | 14.42M +4.0M (+37.9%) | 0.93% +0.184 pp | 4.68% +0.364 pp | USD39.80 +3.5% | 8 qtrs — |
| 36 | LOGOS GLOBAL MANAGEMENT LP | 315.0K +115.0K (+57.5%) | 12.98M +5.1M (+64.9%) | 0.83% +0.275 pp | 0.78% +0.079 pp | USD40.03 +2.9% | 2 qtrs — |
| 37 | CANDRIAM S.C.A. | 311.2K +9.7K (+3.2%) | 12.82M +961.8K (+8.1%) | 0.82% -0.018 pp | 0.06% +0.002 pp | USD23.01 +79.1% | 4 qtrs — |
| 38 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 275.0K +125.0K (+83.3%) | 11.33M +5.4M (+92.0%) | 0.73% +0.309 pp | 0.56% +0.163 pp | USD40.20 +2.5% | 2 qtrs — |
| 39 | TANG CAPITAL MANAGEMENT LLC | 264.7K +— (+0.0%) | 10.91M +492.3K (+4.7%) | 0.70% -0.039 pp | 0.54% +0.138 pp | USD13.67 +201.5% | 10 qtrs — |
| 40 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 250.8K +57.8K (+29.9%) | 10.34M +2.7M (+36.1%) | 0.66% +0.125 pp | 0.00% +0.000 pp | USD32.27 +27.7% | 7 qtrs — |
| 41 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 246.8K +246.8K (+100.0%) | 10.17M +10.2M (+100.0%) | 0.65% +0.653 pp | 0.08% +0.080 pp | USD41.21 +0.0% | 3 qtrs — |
| 42 | IRON TRIANGLE PARTNERS LP | 230.7K +230.7K (+100.0%) | 9.51M +9.5M (+100.0%) | 0.61% +0.611 pp | 1.09% +1.087 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 43 | MORGAN STANLEY | 228.0K +150.5K (+194.1%) | 9.40M +6.3M (+208.0%) | 0.60% +0.387 pp | 0.00% +0.000 pp | USD34.88 +18.1% | 10 qtrs — |
| 44 | WOODLINE PARTNERS LP | 213.1K +170.4K (+399.1%) | 8.78M +7.1M (+422.6%) | 0.56% +0.445 pp | 0.03% +0.026 pp | USD38.05 +8.3% | 7 qtrs — |
| 45 | DIMENSIONAL FUND ADVISORS LP | 210.7K +202.0K (+2,324.6%) | 8.68M +8.3M (+2,439.2%) | 0.56% +0.533 pp | 0.00% +0.002 pp | USD41.13 +0.2% | 2 qtrs — |
| 46 | NORTHERN TRUST CORP | 207.2K +49.7K (+31.6%) | 8.54M +2.3M (+37.8%) | 0.55% +0.109 pp | 0.00% +0.000 pp | USD29.34 +40.5% | 9 qtrs — |
| 47 | SQUAREPOINT OPS LLC | 207.1K +207.1K (+100.0%) | 8.54M +8.5M (+100.0%) | 0.55% +0.548 pp | 0.01% +0.009 pp | USD41.21 +0.0% | 8 qtrs — |
| 48 | WALLEYE CAPITAL LLC | 205.8K +64.7K (+45.8%) | 8.48M +2.9M (+52.7%) | 0.54% +0.151 pp | 0.03% +0.005 pp | USD37.80 +9.0% | 8 qtrs — |
| 49 | ARTIA GLOBAL PARTNERS LP | 205.1K +96.4K (+88.6%) | 8.45M +4.2M (+97.6%) | 0.54% +0.239 pp | 1.35% +0.671 pp | USD40.22 +2.5% | 2 qtrs — |
| 50 | NUVEEN, LLC | 190.6K +147.4K (+340.8%) | 7.86M +6.2M (+361.7%) | 0.50% +0.384 pp | 0.00% +0.002 pp | USD35.98 +14.5% | 4 qtrs — |
| 51 | SCHONFELD STRATEGIC ADVISORS LLC | 182.6K +54.4K (+42.4%) | 7.53M +2.5M (+49.1%) | 0.48% +0.125 pp | 0.03% +0.005 pp | USD25.35 +62.6% | 3 qtrs — |
| 52 | ATOM INVESTORS LP | 181.9K +120.8K (+197.9%) | 7.49M +5.1M (+212.0%) | 0.48% +0.311 pp | 0.60% +0.413 pp | USD40.59 +1.5% | 2 qtrs — |
| 53 | BARCLAYS PLC | 176.3K +134.6K (+322.9%) | 7.27M +6.1M (+536.6%) | 0.47% +0.350 pp | 0.00% +0.002 pp | USD36.90 +11.7% | 9 qtrs — |
| 54 | AMERIPRISE FINANCIAL INC | 155.2K +51.4K (+49.5%) | 6.39M +2.3M (+56.6%) | 0.41% +0.121 pp | 0.00% +0.001 pp | USD32.45 +27.0% | 3 qtrs — |
| 55 | D. E. SHAW & CO., INC. | 154.7K +123.1K (+389.3%) | 6.37M +5.1M (+412.4%) | 0.41% +0.321 pp | 0.00% +0.003 pp | USD40.83 +0.9% | 2 qtrs — |
| 56 | PATIENT SQUARE CAPITAL LP | 150.0K +25.0K (+20.0%) | 6.18M +1.3M (+25.7%) | 0.40% +0.048 pp | 1.32% +0.008 pp | USD39.66 +3.9% | 2 qtrs — |
| 57 | ATIKA CAPITAL MANAGEMENT LLC | 134.5K +134.5K (+100.0%) | 5.54M +5.5M (+100.0%) | 0.36% +0.356 pp | 0.58% +0.584 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 58 | ENSIGN PEAK ADVISORS, INC | 134.4K +— (+0.0%) | 5.54M +250.0K (+4.7%) | 0.36% -0.020 pp | 0.01% +0.001 pp | USD18.63 +121.2% | 3 qtrs — |
| 59 | ALGERT GLOBAL LLC | 130.3K +130.3K (+100.0%) | 5.37M +5.4M (+100.0%) | 0.34% +0.345 pp | 0.08% +0.084 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 60 | AFFINITY ASSET ADVISORS, LLC | 115.0K -147.1K (-56.1%) | 4.74M -5.6M (-54.0%) | 0.30% -0.427 pp | 0.27% -0.628 pp | USD39.35 +4.7% | 2 qtrs — |
| 61 | INVESCO LTD. | 101.5K +56.6K (+125.9%) | 4.18M +2.4M (+136.6%) | 0.27% +0.143 pp | 0.00% +0.000 pp | USD37.20 +10.8% | 7 qtrs — |
| 62 | PFM HEALTH SCIENCES, LP | 99.6K +31.7K (+46.8%) | 4.10M +1.4M (+53.7%) | 0.26% +0.074 pp | 0.41% +0.204 pp | USD39.94 +3.2% | 2 qtrs — |
| 63 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 98.6K -75.0K (-43.2%) | 4.06M -2.8M (-40.5%) | 0.26% -0.224 pp | 0.38% -0.376 pp | USD29.95 +37.6% | 6 qtrs — |
| 64 | RUSSELL INVESTMENTS GROUP, LTD. | 88.3K +86.7K (+5,356.7%) | 3.64M +3.6M (+5,614.6%) | 0.23% +0.229 pp | 0.00% +0.004 pp | USD41.18 +0.1% | 2 qtrs — |
| 65 | SUMMITTX CAPITAL, L.P. | 87.9K +87.9K (+100.0%) | 3.62M +3.6M (+100.0%) | 0.23% +0.233 pp | 0.11% +0.109 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 66 | NEUBERGER BERMAN GROUP LLC | 87.8K +87.8K (+100.0%) | 3.62M +3.6M (+100.0%) | 0.23% +0.232 pp | 0.00% +0.003 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 67 | EAM INVESTORS, LLC | 84.6K -1.7K (-2.0%) | 3.49M +145.6K (+4.4%) | 0.22% -0.017 pp | 0.39% +0.005 pp | USD39.35 +4.7% | 2 qtrs — |
| 68 | STEMPOINT CAPITAL LP | 79.3K +37.9K (+91.6%) | 3.27M +1.6M (+100.6%) | 0.21% +0.094 pp | 0.56% +0.234 pp | USD40.24 +2.4% | 2 qtrs — |
| 69 | BANK OF NEW YORK MELLON CORP | 75.1K +12.7K (+20.3%) | 3.10M +639.6K (+26.0%) | 0.20% +0.025 pp | 0.00% +0.000 pp | USD30.94 +33.2% | 8 qtrs — |
| 70 | AMERICAN CENTURY COMPANIES INC | 72.8K +10.4K (+16.8%) | 3.00M +546.4K (+22.3%) | 0.19% +0.019 pp | 0.00% +0.000 pp | USD30.22 +36.4% | 8 qtrs — |
| 71 | RAFFERTY ASSET MANAGEMENT, LLC | 57.9K +40.5K (+233.9%) | 2.39M +1.7M (+249.7%) | 0.15% +0.105 pp | 0.01% +0.006 pp | USD36.64 +12.5% | 6 qtrs — |
| 72 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 51.7K +39.8K (+333.4%) | 2.14M +1.7M (+355.3%) | 0.14% +0.104 pp | 0.02% +0.021 pp | USD40.78 +1.1% | 2 qtrs — |
| 73 | HIGHVISTA STRATEGIES LLC | 48.5K -5.7K (-10.6%) | 2.00M -135.7K (-6.4%) | 0.13% -0.023 pp | 0.51% -0.009 pp | USD35.25 +16.9% | 6 qtrs — |
| 74 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 48.5K +48.5K (+100.0%) | 2.00M +2.0M (+100.0%) | 0.13% +0.128 pp | 0.01% +0.007 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 75 | TWO SIGMA INVESTMENTS, LP | 48.4K +48.4K (+100.0%) | 1.99M +2.0M (+100.0%) | 0.13% +0.128 pp | 0.00% +0.003 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 76 | CINCTIVE CAPITAL MANAGEMENT LP | 45.9K +45.9K (+100.0%) | 1.89M +1.9M (+100.0%) | 0.12% +0.122 pp | 0.10% +0.102 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 77 | JANE STREET GROUP, LLC | 45.8K +45.8K (+100.0%) | 1.89M +1.9M (+100.0%) | 0.12% +0.121 pp | 0.00% +0.000 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 78 | JPMORGAN CHASE & CO | 42.6K -25.5K (-37.4%) | 1.76M -923.5K (-34.5%) | 0.11% -0.077 pp | 0.00% 0.000 pp | USD37.87 +8.8% | 10 qtrs — |
| 79 | MOODY ALDRICH PARTNERS LLC | 41.3K -2.0K (-4.6%) | 1.70M -1.4K (-0.1%) | 0.11% -0.012 pp | 0.32% -0.006 pp | USD18.14 +127.2% | 4 qtrs — |
| 80 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 39.5K +17.6K (+80.5%) | 1.63M +766.5K (+89.1%) | 0.10% +0.043 pp | 0.01% +0.003 pp | USD40.18 +2.6% | 2 qtrs — |
| 81 | PNC FINANCIAL SERVICES GROUP, INC. | 37.2K +— (+0.0%) | 1.53M +69.2K (+4.7%) | 0.10% -0.005 pp | 0.00% 0.000 pp | USD29.75 +38.5% | 8 qtrs — |
| 82 | ALPS ADVISORS INC | 35.2K +19.6K (+125.2%) | 1.45M +835.8K (+135.9%) | 0.09% +0.050 pp | 0.01% +0.005 pp | USD35.52 +16.0% | 7 qtrs — |
| 83 | FRED ALGER MANAGEMENT, LLC | 33.5K -11.8K (-26.1%) | 1.38M -403.8K (-22.7%) | 0.09% -0.038 pp | 0.01% -0.002 pp | USD39.35 +4.7% | 2 qtrs — |
| 84 | RENAISSANCE TECHNOLOGIES LLC | 32.1K +32.1K (+100.0%) | 1.32M +1.3M (+100.0%) | 0.08% +0.085 pp | 0.00% +0.002 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 85 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 32.0K +23.6K (+281.2%) | 1.32M +988.6K (+298.7%) | 0.08% +0.061 pp | 0.00% +0.001 pp | USD37.45 +10.0% | 6 qtrs — |
| 86 | TD ASSET MANAGEMENT INC | 31.8K +4.1K (+14.8%) | 1.31M +220.1K (+20.2%) | 0.08% +0.007 pp | 0.00% +0.000 pp | USD39.59 +4.1% | 2 qtrs — |
| 87 | SWISS NATIONAL BANK | 31.4K +31.4K (+100.0%) | 1.29M +1.3M (+100.0%) | 0.08% +0.083 pp | 0.00% +0.001 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 88 | RHUMBLINE ADVISERS | 31.0K +5.0K (+19.3%) | 1.28M +255.5K (+25.0%) | 0.08% +0.010 pp | 0.00% +0.000 pp | USD30.57 +34.8% | 7 qtrs — |
| 89 | WELLS FARGO & COMPANY/MN | 29.0K +16.6K (+133.9%) | 1.19M +706.5K (+145.0%) | 0.08% +0.042 pp | 0.00% +0.000 pp | USD35.17 +17.2% | 10 qtrs — |
| 90 | SUPERSTRING CAPITAL MANAGEMENT LP | 26.2K +26.2K (+100.0%) | 1.08M +1.1M (+100.0%) | 0.07% +0.070 pp | 0.58% +0.579 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 91 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 25.6K +6.8K (+36.3%) | 1.05M +311.3K (+42.1%) | 0.07% +0.015 pp | 0.00% +0.000 pp | USD39.85 +3.4% | 2 qtrs — |
| 92 | JAIN GLOBAL LLC | 23.7K +12.6K (+113.0%) | 976.4K +538.7K (+123.1%) | 0.06% +0.032 pp | 0.00% +0.003 pp | USD40.34 +2.2% | 2 qtrs — |
| 93 | ENGINEERS GATE MANAGER LP | 23.4K +3.0K (+14.7%) | 963.5K +161.6K (+20.1%) | 0.06% +0.005 pp | 0.01% +0.002 pp | USD39.59 +4.1% | 2 qtrs — |
| 94 | TWO SIGMA ADVISERS, LP | 22.0K +22.0K (+100.0%) | 906.6K +906.6K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.002 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 95 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 21.7K -151.5K (-87.5%) | 894.3K -5.9M (-86.9%) | 0.06% -0.426 pp | 0.00% -0.001 pp | USD36.20 +13.8% | 4 qtrs — |
| 96 | PROFUND ADVISORS LLC | 21.3K +21.3K (+100.0%) | 879.4K +879.4K (+100.0%) | 0.06% +0.057 pp | 0.03% +0.027 pp | USD41.21 +0.0% | 1 qtrs NEW |
| 97 | ARROWMARK COLORADO HOLDINGS LLC | 20.8K +— (+0.0%) | 856.7K +38.7K (+4.7%) | 0.06% -0.003 pp | 0.02% +0.004 pp | USD13.67 +201.5% | 10 qtrs — |
| 98 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 20.0K +20.0K (+100.0%) | 824.2K +824.2K (+100.0%) | 0.05% +0.053 pp | 0.02% +0.025 pp | USD41.21 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.25
Bullish
Ratio by volume
2.92
Bullish
Buys
9
Sells
4
Shares acquired
51.5K
Shares disposed
17.6K
Cash buys
—
Cash sales
2.00
Net activity
+33,807
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | Violin Jonathan | Director | A-Award | A | Stock Option (Right to Buy) | 6,090 | 89.63 | 545.8K | 6,090 | D | ↗ |
| 2026-05-21 | Soteropoulos Paula | Director | A-Award | A | Stock Option (Right to Buy) | 6,090 | 89.63 | 545.8K | 6,090 | D | ↗ |
| 2026-05-21 | Romano Steven J. | Director | A-Award | A | Stock Option (Right to Buy) | 6,090 | 89.63 | 545.8K | 6,090 | D | ↗ |
| 2026-05-21 | Read Simon | Director | A-Award | A | Stock Option (Right to Buy) | 6,090 | 89.63 | 545.8K | 6,090 | D | ↗ |
| 2026-05-21 | McGeorge Anne | Director | A-Award | A | Stock Option (Right to Buy) | 6,090 | 89.63 | 545.8K | 6,090 | D | ↗ |
| 2026-05-21 | Lawton Alison Frances | Director | A-Award | A | Stock Option (Right to Buy) | 6,090 | 89.63 | 545.8K | 6,090 | D | ↗ |
| 2026-05-21 | KANGO SUJAY | Director | A-Award | A | Stock Option (Right to Buy) | 6,090 | 89.63 | 545.8K | 6,090 | D | ↗ |
| 2026-05-08 | Soteropoulos Paula | Director | S-Sale | D | Common Stock | 599 | 85.47 | 51.2K | 0 | D | ↗ |
| 2026-04-09 | Savitz Ryan | Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,224 | 17.88 | 147.0K | 71,776 | D | ↗ |
| 2026-03-31 | Soteropoulos Paula | Director | S-Sale | D | Common Stock | 599 | 80.11 | 48.0K | 0 | D | ↗ |
| 2026-03-31 | Savitz Ryan | Officer | M-Exempt | A | Common Stock | 74,367 | 8.44 | 627.7K | 74,367 | D | ↗ |
| 2026-03-24 | Soteropoulos Paula | Director | M-Exempt | A | Common Stock | 27,594 | 8.44 | 232.9K | 27,594 | D | ↗ |
| 2026-03-16 | Garcia Marino | Director / Officer | M-Exempt | A | Common Stock | 5,592 | 17.88 | 100.0K | 65,292 | D | ↗ |
| 2026-03-12 | Randhawa Simrat | Officer | S-Sale | D | Common Stock | 33,830 | 81.48 | 2.76M | 0 | D | ↗ |
| 2026-03-12 | Garcia Marino | Director / Officer | S-Sale | D | Common Stock | 900 | 85.53 | 77.0K | 0 | D | ↗ |
| 2026-03-12 | CARR EDWARD | Officer | S-Sale | D | Common Stock | 3,865 | 82.66 | 319.5K | 500 | D | ↗ |
| 2026-02-03 | Veness Adam M | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 52.46 | 5.25M | 100,000 | D | ↗ |
| 2026-02-03 | Savitz Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 52.46 | 7.87M | 150,000 | D | ↗ |
| 2026-02-03 | Randhawa Simrat | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 52.46 | 7.87M | 150,000 | D | ↗ |
| 2026-02-03 | Garcia Marino | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 355,000 | 52.46 | 18.62M | 355,000 | D | ↗ |
| 2026-02-03 | CARR EDWARD | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 52.46 | 2.89M | 55,000 | D | ↗ |
| 2025-12-04 | Savitz Ryan | Officer | M-Exempt | A | Stock Option (Right to Buy) | 20,000 | 8.44 | 168.8K | 84,766 | D | ↗ |
| 2025-11-14 | Randhawa Simrat | Officer | M-Exempt | D | Stock Option (Right to Buy) | 31,250 | 22.07 | 689.7K | 118,750 | D | ↗ |
| 2025-11-13 | Randhawa Simrat | Officer | S-Sale | D | Common Stock | 18,576 | 37.72 | 700.7K | 4,000 | D | ↗ |
| 2025-09-30 | Garcia Marino | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 39.35 | 4.72M | 120,000 | D | ↗ |
| 2025-09-23 | Savitz Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 37.87 | 2.27M | 60,000 | D | ↗ |
| 2025-09-23 | Randhawa Simrat | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 37.87 | 2.27M | 60,000 | D | ↗ |
| 2025-09-09 | Savitz Ryan | Officer | M-Exempt | A | Stock Option (Right to Buy) | 20,000 | 8.44 | 168.8K | 104,766 | D | ↗ |
| 2025-05-22 | Violin Jonathan | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 18.36 | 229.5K | 12,500 | D | ↗ |
| 2025-05-22 | Soteropoulos Paula | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 18.36 | 229.5K | 12,500 | D | ↗ |
| 2025-05-22 | Romano Steven J. | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 18.36 | 229.5K | 12,500 | D | ↗ |
| 2025-05-22 | Read Simon | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 18.36 | 459.0K | 25,000 | D | ↗ |
| 2025-05-22 | McGeorge Anne | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 18.36 | 229.5K | 12,500 | D | ↗ |
| 2025-05-22 | Lawton Alison Frances | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 18.36 | 229.5K | 12,500 | D | ↗ |
| 2025-03-04 | KANGO SUJAY | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-03 | Veness Adam M | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 22.07 | 2.21M | 100,000 | D | ↗ |
| 2025-02-03 | Savitz Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 22.07 | 3.31M | 150,000 | D | ↗ |
| 2025-02-03 | Randhawa Simrat | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 22.07 | 3.31M | 150,000 | D | ↗ |
| 2025-02-03 | Garcia Marino | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 340,000 | 22.07 | 7.50M | 340,000 | D | ↗ |
| 2025-02-03 | CARR EDWARD | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 22.07 | 1.32M | 60,000 | D | ↗ |
| 2024-09-27 | Fairmount Funds Management LLC | Director | J-Other | D | Common Stock | 62,146 | 0.00 | — | 0 | I | ↗ |
| 2024-09-16 | Romano Steven J. | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 26.42 | 581.2K | 22,000 | — | ↗ |
| 2024-05-23 | Violin Jonathan | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 21.77 | 239.5K | 11,000 | — | ↗ |
| 2024-05-23 | Veness Adam M | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 21.77 | 1.63M | 75,000 | — | ↗ |
| 2024-05-23 | Soteropoulos Paula | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 21.77 | 239.5K | 11,000 | — | ↗ |
| 2024-05-23 | Savitz Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 21.77 | 2.18M | 100,000 | — | ↗ |
| 2024-05-23 | Randhawa Simrat | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 21.77 | 2.18M | 100,000 | — | ↗ |
| 2024-05-23 | McGeorge Anne | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 21.77 | 239.5K | 11,000 | — | ↗ |
| 2024-05-23 | MOULDER LEON O JR | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 21.77 | 239.5K | 11,000 | — | ↗ |
| 2024-05-23 | Lawton Alison Frances | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 21.77 | 239.5K | 11,000 | — | ↗ |
| 2024-05-23 | Garcia Marino | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 243,000 | 21.77 | 5.29M | 243,000 | — | ↗ |
| 2024-05-23 | Fairmount Funds Management LLC | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 21.77 | 239.5K | 11,000 | — | ↗ |
| 2024-05-23 | CARR EDWARD | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 21.77 | 1.31M | 60,000 | — | ↗ |
| 2024-04-01 | Fairmount Funds Management LLC | Director | J-Other | A | Common Stock | 58,857 | 0.00 | — | 2,700,691 | — | ↗ |
| 2024-01-24 | Veness Adam M | Officer | A-Award | A | Stock Option (Right to Buy) | 110,000 | 17.88 | 1.97M | 110,000 | — | ↗ |
| 2024-01-24 | Savitz Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 17.88 | 2.15M | 120,000 | — | ↗ |
| 2024-01-24 | Randhawa Simrat | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 17.88 | 2.15M | 120,000 | — | ↗ |
| 2024-01-24 | Garcia Marino | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 17.88 | 4.92M | 275,000 | — | ↗ |
| 2024-01-24 | CARR EDWARD | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 17.88 | 1.43M | 80,000 | — | ↗ |
| 2024-01-22 | Meng Lei | Director | A-Award | A | Common Stock | 1,500,000 | 12.00 | 18.00M | 2,717,554 | — | ↗ |
| 2024-01-22 | MOULDER LEON O JR | Director | A-Award | A | Common Stock | 166,667 | 12.00 | 2.00M | 1,436,745 | — | ↗ |
| 2024-01-22 | Fairmount Funds Management LLC | Director / 10% Owner | A-Award | A | Common Stock | 834,334 | 12.00 | 10.01M | 2,762,837 | — | ↗ |
| 2023-09-29 | Fairmount Funds Management LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 24,670 | 13.63 | 336.3K | 1,928,503 | — | ↗ |
| 2023-09-26 | Fairmount Funds Management LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 30,000 | 13.15 | 394.5K | 1,903,833 | — | ↗ |
| 2023-09-19 | Fairmount Funds Management LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 30,000 | 13.20 | 396.0K | 1,873,833 | — | ↗ |
| 2023-09-13 | Fairmount Funds Management LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 9,367 | 11.76 | 110.2K | 1,843,833 | — | ↗ |
| 2023-09-12 | Fairmount Funds Management LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 14,887 | 10.85 | 161.5K | 1,834,466 | — | ↗ |
| 2023-09-11 | Fairmount Funds Management LLC | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 6,500 | 11.20 | 72.8K | 6,500 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-19.3K
Shares Outstanding
41.75M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Marino Garcia President and Chief Executive Officer | 630.0K | — | — | 9.45M | 519.8K | 14.0K | 10.61M | 89.04% | ↗ |
| 2 | 2025 | Simrat Randhawa, M.D. Executive Vice President, Head of Research and Development | 530.6K | — | — | 4.29M | 388.1K | 14.0K | 5.22M | 82.14% | ↗ |
| 3 | 2025 | Ryan Savitz Executive Vice President, Chief Financial Officer, Chief Business Officer and Treasurer | 482.6K | — | — | 4.29M | 289.5K | 14.0K | 5.07M | 84.51% | ↗ |
| 4 | 2024 | Marino Garcia President and Chief Executive Officer | 600.0K | — | — | 7.90M | 330.0K | 13.8K | 8.84M | 89.33% | ↗ |
| 5 | 2024 | Marino Garcia President and Chief Executive Officer | 600.0K | — | — | 7.90M | 330.0K | 13.8K | 8.84M | 89.33% | ↗ |
| 6 | 2024 | Simrat Randhawa, M.D. Executive Vice President, Head of Research and Development | 482.0K | — | — | 3.35M | 192.8K | 13.8K | 4.04M | 82.94% | ↗ |
| 7 | 2024 | Simrat Randhawa, M.D. Chief Medical Officer | 482.0K | — | — | 3.35M | 192.8K | 13.8K | 4.04M | 82.94% | ↗ |
| 8 | 2024 | Ryan Savitz Executive Vice President, Chief Financial Officer, Chief Business Officer and Treasurer | 464.0K | — | — | 3.35M | 185.6K | 5.9K | 4.00M | 83.62% | ↗ |
| 9 | 2024 | Ryan Savitz Chief Financial Officer, Chief Business Officer and Treasurer | 464.0K | — | — | 3.35M | 185.6K | 5.9K | 4.00M | 83.62% | ↗ |
| 10 | 2023 | Stephen Mahoney Former President, Chief Financial and Operating Officer | 309.3K | 539.1K | — | 118.3K | — | 690.0K | 1.66M | 7.14% | ↗ |
| 11 | 2023 | Thomas Beetham Former Chief Legal Officer | 300.3K | 523.5K | — | 74.6K | — | 673.1K | 1.57M | 4.74% | ↗ |
| 12 | 2023 | Lisa Olson, Ph.D. Former Chief Scientific Officer | 160.7K | 277.0K | — | 91.9K | — | 598.4K | 1.13M | 8.14% | ↗ |
| 13 | 2023 | Jason Gardner, D.Phil. Former President and Chief Executive Officer | 57.9K | — | — | — | — | 609.8K | 667.6K | 0.00% | ↗ |
| 14 | 2023 | Marino Garcia President and Chief Executive Officer | 174.9K | — | — | — | 321.2K | — | 496.0K | 0.00% | ↗ |
| 15 | 2023 | Simrat Randhawa, M.D. Chief Medical Officer | 139.5K | — | — | — | 198.7K | — | 338.2K | 0.00% | ↗ |
| 16 | 2023 | Ryan Savitz Chief Financial Officer, Chief Business Officer and Treasurer | 135.5K | — | — | — | 194.1K | — | 329.7K | 0.00% | ↗ |
| 17 | 2022 | Jason Gardner, D.Phil. Former President and Chief Executive Officer | 565.0K | — | — | 756.4K | 326.3K | 7.1K | 1.65M | 45.71% | ↗ |
| 18 | 2022 | Stephen Mahoney Former President, Chief Financial and Operating Officer | 448.0K | — | — | 483.7K | 188.2K | 1.0K | 1.12M | 43.15% | ↗ |
| 19 | 2022 | Lisa Olson, Ph.D. Former Chief Scientific Officer | 428.0K | — | — | 373.6K | 179.8K | 2.1K | 983.5K | 37.99% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marino Garcia | President, Chief Executive Officer & Director | 1M | male |
| Simrat Randhawa | Executive Vice President and Head of R&D | 932.7K | male |
| Ryan Savitz | Executive VP, CFO, Chief Business Officer & Treasurer | 786.1K | male |
| Jennifer Davis Ruff | Vice President and Head of Investor Relations & Corporate Affairs. | — | female |
| Judson Taylor | Senior Vice President & Head of Technical Operations | — | male |
| Kristina Maximenko | Chief People Officer | — | female |
| Debra Segal | Head of Regulatory Affairs | — | female |
| Polly Hanff | Head of Quality | — | female |
| Rashieda Gluck | Head of Clinical Development Operations | — | female |
| Scott Nogi | Head of Business Operations | — | male |
| Edward G. Carr | Senior VP & Chief Accounting Officer | — | male |
| Adam Veness | Senior Vice President, General Counsel & Secretary | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DNTH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
